RQ Biotechnology Ltd. Celebrates Milestone with Grant of GB Patent Covering its Licensed Clinical-Stage Antibody for the Prevention and Treatment of COVID-19

RQ Bio is scaling up at speed, with the appointment of Non-Executive Directors, Dr W. Ripley (“Rip”) Ballou and Dr Jacques Cholat to its Board of Directors.

RQ Bio announces that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery

RQ Biotechnology Limited today formalises and strengthens its Executive Committee with three new appointments:

RQ Bio Launches with goal to transform treatment and prevention of viral infectious diseases through antibody technologies